Please assess the completion status of the following clinical trial:

Trial Title: Dose-varied Evaluation of Ablavar-enhanced MR Angiography of the Central Veins of the Chest in Healthy Participants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* healthy male or female subjects between 18-45 years of age~Exclusion Criteria:~* Pregnant and lactating females~* known renal impairment~* allergy to gadolinium-based contrast~* metallic implanted devices~* claustrophobia.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- 0.03 mmol/kg (Type: ACTIVE_COMPARATOR): FDA-approved dose for lower extremity arterial imaging
- 0.02 mmol/kg (Type: EXPERIMENTAL): None
- 0.01 mmol/kg (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).